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Current therapies for systemic lupus erythematosus (SLE) include corticosteroids as a persistent mainstay and
traditional immunosuppressants which are given according to disease severity, organ involvement and patient
status. No treatment entails certain efficacy devoid of mild-to-moderate adverse effects. Nowadays, novel therapies
are being developed aiming to target specific molecules involved in SLE development and progression which show
variable effectiveness and safety. Biologic agents considered for SLE comprise monoclonal antibodies (chimeric,
humanized or fully human) as well as fusion molecules or antibody fragments mostly consisting of B cell-targeted
therapies beside anti-cytokines as well as T cell-targeted therapies. Encouraging evidence on biologics is mostly
provided by case series or uncontrolled studies; conversely, larger randomized controlled clinical trials have
frequently missed their primary endpoints with the exception of BLISS-52 and BLISS-76 trials. Actually, apart from
belimumab, biologics are employed in clinical practice as off-label treatments for lupus and results are often
promising, depending on specific SLE features, dose regimens and individual responsiveness.
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In recent times, hope was raised in systemic lupus ery-
thematosus (SLE) for biologic therapies that are capable
of specific molecular targeting at distinct key points.
Novel therapies tested in SLE comprise anti-cytokines
antibodies (for example, anti-interleukin(IL)-6), anti-B
cell therapies targeting either B cell surface antigens
(anti-CD20, anti-CD22) or B cell survival factors (for
example, anti-BLyS/APRIL monoclonal antibodies), as
well as drugs intervening in B-T cell co-stimulation
(CTLA4-Ig) [1-12]. It has to be noted that with the ex-
ception of belimumab most of these drugs are far from
being dispensed in clinical practice [1,13], and some will
never become available since randomized controlled trials
(RCTs) have missed their primary endpoints despite
promising preliminary results. Hence, apart from beli-
mumab, biological treatment of SLE still remains an
“off-label matter”, raising conflicting opinions on rea-
sons for RCTs’ failure and biologics’ suitability in lupus* Correspondence: adoria@unipd.it
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2014management. The aim of our commentary is to provide
an overview of candidate biological therapies for SLE,
in light of studies which challenge or support their ap-
plicability in clinical practice.
B-cell targeted therapies
B-cell targeted therapies represent the bulk of candidate
biologic medications in SLE, with the key role consistently
played by B cells in disease pathogenesis and progression
[14] (Table 1).
Rituximab and anti-CD20
CD20 is a B lymphocyte restricted cell surface molecule
that is expressed from pre-B to memory B cells, but is
not found in stem cells and plasma cells. Rituximab
(RTX) is a chimeric antibody against the CD20 molecule
which was tested in two RCTs [2,3]. The EXPLORER
(Exploratory Phase II/III SLE Evaluation of Rituximab)
trial was aimed to assess RTX efficacy and safety in
moderate-to-severe active non-renal SLE. RTX depleted
B cells but did not significantly reduce anti-DNA levels.
Unfortunately, no differences in the British Isles Lupus
Assessment Group (BILAG) score and flare-free ratiotd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Biologic therapies proposed for SLEa





Phase III • Significantly decreased anti-dsDNA
antibody titers and increased complement
levels vs. placebo. Significantly decreased
lupus non-renal flares in Hispanic and
African American patients
• Did not significantly improve
lupus outcome in either renal
or non-renal SLE in large




Phase III • Significantly increased complement
levels and decreased anti-dsDNA titers
through week 48 vs. placebo
• No significant improvement
in renal outcome
[15]
• Induced numerically (non-statistically)
significant greater renal response
vs. placebo
• Serious infections in treated




Phase IIb • Provided clinical improvement in patients
receiving ≥2,400 mg cumulative dose
• No significant BILAG






Phase III • Significant improvement in moderate-
persistent active SLE outcome and
decreased flare rates in phase III RCTs
(met primary endpoints)
• No BILAG assessment [8,9]
No data on CNS or severe
renal involvement
• Significant decrease in anti-dsDNA
antibody titers
• No advantages by treatment
continuation through week
76 (but in post-hoc analysis)
• Steroid-sparing effect




Phase II • Not availableb • Serious infections and
decreased immunoglobulin levels
in patients receiving MMF or







Phase IIb • Reduced BILAG A polyarthritis flares
in a phase IIb RCT
• Did not reduce overall
disease flares vs. placebo in





Phase II • Ameliorated SLEDAI in a phase II RCT • No significant superiority
to placebo
[11,12]








• Effective on refractory arthritis,
nephritis and skin lesions in
open-label studies




• Reduction in SLEDAI and SLICC-DI
in pilot studies after short-term
induction treatment









Phase I • Significantly reduced SELENA-SLEDAI
score (main improvement on arthritis)
• Neutropenia and serious
infections
[18]
• Significantly reduced IgG
anti-dsDNA antibody levels





• Improved arthritis in an open-label trial • No long-lasting effect [4]
• No extensive data are






Phase I • Significantly reduced the rate of
disease flares vs. placebo
• No data on severe SLE [19]
• Lower request of immunosupressor
vs. placebo
aOnly biologic therapies for which published clinical studies are currently available are listed.
bthe study was prematurely terminated and no efficacy measures were undertaken.
anti-dsDNA, anti-double stranded DNA; APRIL, A PRoliferation Inducing Ligand; BILAG, British Isles Lupus Assessment Group; BLyS, B Lymphocyte Stimulator; CNS,
central nervous system; IFNα, interferon alpha; IgG, class G immunoglobulin; IL1Ra, interleukin 1 receptor antagonist; IL6R, interleukin-6 receptor; mAb, monoclonal
antibody; MMF, mycophenolate mofetil; RCT, randomized controlled trial; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease
Activity Index; SLICC-DI, Systemic Lupus International Collaborating Clinics group Damage Index; TNFα, tumor necrosis factor alpha.
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Rituximab (LUNAR) study involved patients with prolifera-
tive lupus nephritis (LN) [5]. The primary outcome was the
proportion of patients with complete or partial remission
of LN at 12 months, which was not attained; two deaths
(sepsis and pneumonitis) occurred in the RTX group.
Evaluation of Ocrelizumab (humanized anti-CD20 mono-
clonal antibody, mAb) in two phase III RCTs - the BEGIN
(A Study to Evaluate Two Doses of Ocrelizumab in Patients
With Active Systemic Lupus Erythematosus) and the
BELONG (A Study to Evaluate Ocrelizumab in Patients
With Nephritis Due to Systemic Lupus Erythematosus)
very similar to the EXPLORER and LUNAR - was stopped
prematurely due to an increase in infections in the active
arm of the studies [15].
Different facts can explain the failure of these phase III
RCTs testing CD-20 depleting agents in SLE, for example,
the low number of patients, highly variable background of
immunosuppressive therapy and high dose steroids,
relatively short follow-up period, non-adequate outcome
measures and, importantly, extreme endpoint stringency
(no BILAG A or B, and complete renal response). How-
ever, partial favorable reports for RTX were documented
in that the EXPLORER trial showed a higher percentage
of complete or partial response at week 52 in African
American and Hispanic patients. Statistically significant
improvements in serum complement (C3 and C4) levels
and decreases in anti-dsDNA antibody levels were observed
among RTX-treated patients both in the EXPLORER and
in the LUNAR trials [2,3].
Moreover, open and uncontrolled clinical studies with
RTX as well as results of French, UK and other European
registries indicate promising outcomes [20-22]. Prospective
and retrospective studies, as well as case series and single
case reports, showed 300 patients with refractory LN being
treated with RTX at different dosing regimens and analysis
revealed complete or partial response to RTX in approxi-
mately two thirds of patients [23]. Notably, longitudinal
observations on 50 patients with proliferative LN showed
promising results following treatment with RTX 1 g fort-
night and pulse methylprednisolone but no oral steroids
in the follow-up [24]. In this study, the majority of patients
were kept on partial or complete renal remission with only
mycophenolate mofetil after RTX induction. However, the
definition of renal remission given in this study may be
objectionable and systemic as well as renal flares occurred
in a relevant percentage of patients within one year.
Nevertheless, in light of “experience-based” medicine, RTX
use is included in the European League Against Rheumatism
(EULAR) recommendations for refractory LN [25].
Anti-CD22 and Epratuzumab
Epratuzumab is a humanized monoclonal antibody which
activates the CD22 regulatory pathway on B cells [26]. Itwas tested in a phase IIb trial [5], where it caused a mod-
est decrease of about 30% in B cells, without a change in
immunoglobulin levels. The proportion of responders was
higher in all epratuzumab groups than in placebo, but
overall treatment effect was not statistically significant [5].
Two international RCTs (Alleviate Lupus Affliction with
Epratuzumab and Validate its Autoimmune Safety and
Efficacy (ALLEVIATE) 1 and 2) evaluating epratuzumab
in patients with moderately to severe active SLE were
discontinued prematurely because of interruption in the
drug supply [27]. Despite that, 90 patients with moderate-
to-severe SLE flares responded well to epratuzumab, as
it was indicated by improvements in BILAG scores and
steroid sparing effects. Epratuzumab was well tolerated
and significantly improved health-related quality of life.
Two phase III RCTs are currently ongoing (NCT01261793;
NCT01262365) [5].
BAFF/BLyS and APRIL system and belimumab
Targeting B-cell activating factor (BAFF)/B lymphocyte
stimulator (BLyS) and a proliferation inducing ligand
(APRIL) seems to be a suitable option in lupus. Preclinical
data from experimental models and human observations
confirmed high BLyS concentrations in lupus prone
mice and approximately half of human lupus patients;
BLyS antagonism ameliorated disease symptoms and
survival in animal models [28]. When comparing RTX
and belimumab, one can observe that terminally differen-
tiated B cells are under BLyS influence but do not express
the CD20 molecule, thus belimumab is expected to act
faster, providing a milder immunesuppression, which is
favorable by safety issues.
Up to the present, two phase III RCTs have been per-
formed with belimumab [8,9]. The arrangement and
protocols were similar; therefore combined results have
also been analyzed. Antinuclear antibodies (ANA) or anti-
ds(double stranded)DNA positive patients with moderately
active lupus were targeted. Pooled data from the two trials
indicated that a significantly higher number of patients
achieved good response with both 1 and 10 mg/kg
belimumab at week 52 as compared to the placebo group
[8]. Furthermore, the duration of response was longer in
the treated groups and the higher the belimumab dosage,
the more likely corticosteroids could be reduced. In this
treatment arm, patients flared less frequently as indicated
by the SLE flare index (SFI) and also by flare rates at week
52. Actually, however, the second phase III study, BLISS
76, could not prove a positive sustained effect after 76
weeks [9] and it has to be noted that these studies did not
recruit patients with severe LN or central nervous system
(CNS) involvement. Hence, many aspects in the use of
belimumab remain to be clarified in real-life SLE [29],
including the clinical relevance of the differences in
comparison to the placebo arm; the impact of the
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treatment of refractory severe disease, including renal
and CNS lupus; and finally, the balance between clinical
benefit and cost.
Besides belimumab, sub-cutaneous drugs blocking soluble
or receptor-bound BLyS are currently being tested in phase
III RCTs [1], which in case of efficacy would provide a greater
advantage in terms of administration route (subcutaneous vs.
intravenous) and the patients’ comfort and compliance.
A second drug aimed at suppressing the stimulation of
B cells was atacicept, a chimeric molecule against APRIL.
The phase II study of atacicept in patients with LN was,
however, terminated after recruiting six patients because
of an unexpected decrease in immunoglobulin levels and
an increased number of infections [6].
T–cell targeted therapies
B and T lymphocytes and antigen presenting cells (APCs),
may communicate directly with each other. CTLA4-Ig
(abatacept) is a fusion protein that blocks the interaction
within the CD86/80-CD28 stimulatory molecular pair,
inhibiting the interaction between APCs and T cells, cyto-
kine production and subsequent stimulation of B cells.
Abatacept was tested in two large double-blind RCTs in
non-renal lupus and in patients with LN which did not
meet their primary endpoints in prevention of disease flares
[10], despite studies on animal models providing beneficial
effects [30]. Nevertheless, post-hoc analysis revealed less
frequent flares in treated group as compared to the placebo
[31], suggesting definitions of disease flare might have
blurred clinically meaningful results albeit not statistically
significant. Particularly, abatacept seems to have prevented
BILAG A polyarthritis flares in patients displaying non-life-
threatening SLE manifestations [10].
Other treatment options: TNF-blocking therapies
The role of tumor necrosis factor alpha (TNFα) and its
inhibition in lupus is debated. High levels of TNFα were
demonstrated in human tissue samples [32] and the serum
of SLE patients, where they correlated with disease activity;
mouse models were likewise shown to reflect the same pic-
ture [33]. To date, open-label experience on a small patient
series displaying refractory lupus manifestations brought
to light some positive results. Refractory LN, skin le-
sions, hemophagocytic syndrome and arthritis showed
beneficial effects following TNFα-depleting therapies
[34,35]. Moreover, some pilot studies [17,34] demon-
strated an improvement in Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI) and Systemic Lupus
International Collaborating Clinics (SLICC) index upon
TNFα depletion, suggesting TNFα-blockers could be
taken into account as short-term induction therapy
when dealing with refractory SLE. It is worth noting that
no large controlled studies are yet available on anti-TNFαdepletion in human SLE, therefore, no certain inference
can be made.
Some other cytokines (IL-6, interferon alpha (IFNα))
are being explored as putative future therapeutic targets.
Tocilizumab (anti-IL6R monoclonal antibody) use in a
phase I trial seemed to decrease disease activity [18]. Like-
wise, interference with IFNα signaling might dampen DC
and autoreactive B cells activation [19]. However, the data
set is still very limited and no conclusions can be drawn
on the disease course.
Discussion and conclusions
To date, the only RCTs that succeeded and achieved their
primary endpoints were BLISS-52 and BLISS-76, leading
to approval of belimumab for mild-to-moderate SLE. Beli-
mumab is the first drug dedicated to SLE 50 years after
corticosteroids and antimalarials, meaning no other firm
evidence could be drawn so far for any other treatment
ranging from traditional immunosuppressants to new
biologic drugs. This is probably due to the great het-
erogeneity of the disease [35], which makes it unlikely
that one treatment may be suitable for all patients.
These aspects should be considered when turning to
RCTs, since generalization of results - either promising or
disappointing - is a thorny matter in SLE [36]. Ironically,
most of the target populations enrolled in RCTs are on
the one hand too small to represent the entire disease
variability and especially most severe lupus manifestations,
and on the other hand they are not small enough to focus
on benefits which may be gained by discrete patient sub-
groups, though not by the general population. Consist-
ently, patients belonging to African American or Hispanic
ethnicity showed positive results in RCTs which had glo-
bally failed [23], suggesting study designs are sometimes
objectionable in regard to outcome measures, background
medications (for example, high dose corticosteroids over-
whelming any positive effect of the new drug) or shortness
of follow-up period [1,23]. Moreover, since severely affected
patients (for example, CNS involvement, refractory LN)
are frequently excluded from RCTs, information on an
emerging drug in the case of life-threatening manifesta-
tions is lacking [1]. Though going back to non-controlled
trials or basing conclusions on post-hoc analysis would not
be scientifically acceptable, endpoint definitions should
reasonably correlate with clinical practice in order to
provide useful indications and limit the need for off-label
use of new drugs. Indeed, excessive outcome strin-
gency (for example, no BILAG B allowed, complete
renal response required) is hardly ever met in lupus,
whereas partial remission or improvement in organ-specific
(non-generalized) alterations is far more frequent and
acceptable, yet not optimal [37]. These considerations
aside, it also has to be kept in mind that compelling evi-
dence may diverge from intuitive premises, preclinical
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efficacy of a developing drug or methodological mis-
takes which have to be carefully considered.
Deeper knowledge of the underlying mechanisms of
lupus [35] will hopefully lead to generation of more ef-
fective targeted therapies which would both affect dis-
ease course and minimize treatment-related adverse
events; nevertheless, a detailed picture of patient status
[38] will always be required for the most suitable thera-
peutic approach to be tailored.
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